AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2022
Sep 16, 2022
32312_dirs_2022-09-16_c55ea0aa-7b6a-4a5b-8001-be44b2efe523.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-09-14
Reporting Person: Belldegrun Arie (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-14 | Ordinary Shares | M | 160000 | $5 | Acquired | 408693 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-09-14 | Stock Option (right to buy) | $5 | M | 160000 | Disposed | 2022-10-07 | Ordinary Shares (160000) | Direct |
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11